A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 12, 2026 341 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MajesTEC-3 study Source RELATED ARTICLESMORE FROM AUTHOR Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism EMA Recommends Extension of Indications for Ponatinib Associated with a New Pharmaceutical Form and a New Strength MOST POPULAR Moving Beyond BMI: Low Muscle Mass May Affect Cancer Survival April 30, 2018 10 Tips for Healthy Eating After Cancer Treatment December 7, 2020 Scientists Focus on Fusion Proteins in Childhood Cancers August 4, 2020 Making Important Decisions During Cancer: A Survivor’s Story October 26, 2021 Load more HOT NEWS ASCO20 Virtual Research Round Up Podcast: Breast Cancer, Sarcoma, and Supportive... What You Should Know About Receiving Online Medical Test Results and... 4-Year-Old Secretly Told Teacher His Dad Was Sick, And She Donated... When Used Together, Chemo and Cardiac Drug Improve Chances of Cancer...
